Galmed pharmaceuticals posts q4 loss per share of $0.39

Galmed pharmaceuticals provides business update and reports fourth quarter and year end 2019 financial results.qtrly loss per share of $0.39.galmed pharmaceuticals - cash & cash equivalents, restricted cash, short-term deposits,marketable debt securities totaled $75.6 million as of dec 31, 2019.q4 earnings per share view $-0.34 -- refinitiv ibes data.

GLMD Ratings Summary

GLMD Quant Ranking